Core Viewpoint - Nuvectis Pharma, Inc. is advancing its clinical-stage drug candidate NXP900, a novel YES1/SRC kinase inhibitor, with upcoming presentations at the 2025 American Association for Cancer Research Meeting, highlighting its potential in treating advanced solid tumors and overcoming drug resistance in non-small cell lung cancer (NSCLC) [1][2]. Group 1: NXP900 Development - NXP900 is currently in a Phase 1a dose escalation study, demonstrating potent single-agent activity and synergy with ALK inhibitors in ALK-resistant NSCLC models [2][4]. - The drug targets YAP1 signaling in NSCLC cell lines and shows sensitivity in endocrine therapy-resistant luminal A breast cancer cell lines [2][4]. Group 2: Presentation Details - Nuvectis will present findings related to NXP900 in various sessions at the 2025 AACR Meeting, including "First-in-Human Phase I Clinical Trials" and "Drug Resistance in Molecular Targeted Therapies," scheduled for April 29th [3]. - Specific presentation times include sessions from 9:00 AM to 12:00 PM and 2:00 PM to 5:00 PM on the same day [3]. Group 3: Company Overview - Nuvectis Pharma, Inc. focuses on developing innovative precision medicines for serious unmet medical needs in oncology, with two clinical-stage candidates: NXP800 and NXP900 [4]. - NXP800 is an oral small molecule GCN2 activator in trials for platinum-resistant ovarian carcinoma and cholangiocarcinoma, while NXP900 is an oral small molecule inhibitor of the SRC Family of Kinases [4].

FORT LEE, NJ, March 14, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (“Nuvectis”, “Company”), a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, Chairman and Chief Executive Officer, will participate in a fireside chat at the 37th Annual Roth Conference taking place March 17th-19th in Dana Point, California. Event37th Annual Roth ConferenceDateMarch 17, 2025Tim ...

Core Insights - Nuvectis Pharma, Inc. announced a new publication demonstrating that the combination of NXP900 and osimertinib is superior to osimertinib alone in treating EGFR-mutated non-small cell lung cancer (NSCLC) [1] - The study showed decreased cell proliferation and increased apoptosis in vitro, supporting the rationale for combining NXP900 with EGFR inhibitors [1] - Nuvectis is progressing towards the initiation of the Phase 1b program for NXP900, with a Phase 1a dose escalation study nearing completion [2] Company Overview - Nuvectis Pharma is focused on developing innovative precision medicines for serious unmet medical needs in oncology, currently working on two clinical-stage drug candidates: NXP800 and NXP900 [3] - NXP800 is in a Phase 1b clinical trial for platinum-resistant, ARID1a-mutated ovarian carcinoma, while NXP900 is an oral small molecule inhibitor of SRC Family Kinases, currently in a Phase 1a dose escalation study [3]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to . Commission File Number 001-41264 NUVECTIS PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 86-2405608 (State or Other Juris ...

Financial Performance - Nuvectis reported a net loss of $19.0 million for the year ended December 31, 2024, a decrease of $3.3 million compared to a net loss of $22.3 million in 2023[6]. - The basic and diluted net loss per common share was $1.11 for 2024, compared to $1.43 for 2023[15]. - The total stockholders' equity decreased to $9.7 million as of December 31, 2024, from $12.2 million in 2023[13]. Expenses - Research and development expenses were $12.9 million for 2024, down from $15.4 million in 2023, reflecting a decrease of $2.5 million[6]. - General and administrative expenses decreased to $6.9 million in 2024 from $7.5 million in 2023, a reduction of $0.6 million[7]. - Interest income increased to $0.8 million in 2024, compared to $0.6 million in 2023, marking an increase of $0.2 million[7]. Cash Position - Cash and cash equivalents as of December 31, 2024, were $18.5 million, a slight decrease from $19.1 million as of December 31, 2023[5]. - The company completed a follow-on offering in February 2025, raising $15.5 million in gross proceeds, extending its cash runway into 2027[4]. Clinical Trials - NXP800 is currently in a Phase 1b clinical trial for ARID1a-deficient ovarian cancer, with updated results expected in Q2 2025[4]. - Enrollment for the NXP900 Phase 1a dose escalation study is ongoing, with plans to start the Phase 1b program in mid-2025[4].

NXP800 Phase 1b study in patients with platinum resistant, ARID1a-mutated ovarian cancer is ongoing; Orphan Drug Designation granted by the U.S. FDA. Updated Phase 1b results anticipated in Q2 2025NXP900 Phase 1a dose escalation study continues to enroll, preparation for the start of the Phase 1b program is underway. Phase 1b program expected to begin in mid-2025Follow-on offering completed in February 2025 extends cash runway into 2027 FORT LEE, N.J., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. ...

Core Viewpoint - Nuvectis Pharma, Inc. has successfully closed a public offering of 2,700,000 shares, raising approximately $15.5 million to support its oncology drug development programs [1][2]. Group 1: Offering Details - The public offering included an additional 405,000 shares purchased by the underwriter, Lucid Capital Markets, at a price of $5.00 per share [1][2]. - The gross proceeds from the offering are approximately $15.5 million, before underwriting discounts and commissions [1]. Group 2: Use of Proceeds - Nuvectis plans to utilize the net proceeds for advancing the development of its drug candidates NXP800 and NXP900, hiring additional personnel, capital expenditures, and general corporate purposes [2]. Group 3: Company Overview - Nuvectis Pharma focuses on developing innovative precision medicines for serious oncology conditions with unmet medical needs [5]. - The company is currently advancing two clinical-stage drug candidates: NXP800, which is in a Phase 1b trial for platinum-resistant, ARID1a-mutated ovarian carcinoma, and NXP900, which is in a Phase 1a dose escalation study [5].

Core Viewpoint - Nuvectis Pharma, Inc. has successfully closed a public offering of 2,700,000 shares, raising approximately $15.5 million to support its oncology drug development programs [1][2]. Group 1: Offering Details - The public offering included an additional 405,000 shares purchased by the underwriter, Lucid Capital Markets, at a price of $5.00 per share [1][2]. - The gross proceeds from the offering are approximately $15.5 million, before deducting underwriting discounts and commissions [1]. Group 2: Use of Proceeds - Nuvectis plans to utilize the net proceeds for advancing the development of its drug candidates NXP800 and NXP900, hiring additional personnel, capital expenditures, and general corporate purposes [2]. Group 3: Company Overview - Nuvectis Pharma focuses on developing innovative precision medicines for serious oncology conditions with unmet medical needs [5]. - The company is advancing two clinical-stage drug candidates: NXP800, which is in a Phase 1b trial for platinum-resistant, ARID1a-mutated ovarian carcinoma, and NXP900, currently in a Phase 1a dose escalation study [5].

Core Viewpoint - Nuvectis Pharma, Inc. has announced a public offering of 2,700,000 shares at $5.00 per share, aiming for gross proceeds of $13.5 million to support its oncology drug development programs [1][2]. Group 1: Offering Details - The public offering consists of 2,700,000 shares priced at $5.00 each, with expected gross proceeds of $13.5 million [1]. - An underwriter has been granted a 30-day option to purchase up to 405,000 additional shares at the public offering price [1]. - The offering is expected to close on February 6, 2025, subject to customary closing conditions [1]. Group 2: Use of Proceeds - Nuvectis intends to utilize the net proceeds for advancing development programs of drug candidates NXP800 and NXP900, hiring additional personnel, capital expenditures, and general corporate purposes [2]. Group 3: Company Overview - Nuvectis Pharma focuses on developing innovative precision medicines for serious oncology conditions with unmet medical needs [5]. - The company is currently advancing two clinical-stage drug candidates: NXP800, which is in a Phase 1b trial for platinum-resistant, ARID1a-mutated ovarian carcinoma, and NXP900, which is in a Phase 1a dose escalation study [5].

Core Viewpoint - Nuvectis Pharma, Inc. has initiated an underwritten public offering of its common stock to support the development of its clinical-stage drug candidates and other corporate purposes [1][2]. Group 1: Offering Details - The public offering will consist of shares solely offered by Nuvectis, with an option for underwriters to purchase an additional 15% of the shares within 30 days [1]. - Lucid Capital Markets is serving as the sole book runner for the offering [2]. - The offering is subject to market conditions and there is no assurance regarding its completion or the final terms [1]. Group 2: Use of Proceeds - Nuvectis plans to utilize the net proceeds from the offering for advancing the development of drug candidates NXP800 and NXP900, hiring personnel, capital expenditures, and general corporate purposes [2]. Group 3: Company Overview - Nuvectis Pharma focuses on developing innovative precision medicines for serious oncology conditions with unmet medical needs [5]. - The company is advancing two clinical-stage drug candidates: NXP800, which is in a Phase 1b trial for platinum-resistant, ARID1a-mutated ovarian carcinoma, and NXP900, currently in a Phase 1a dose escalation study [5].